Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, double blind, single dose, placebo-controlled study to evaluate pharmacokinetics, safety and tolerability of ZYBK2 in healthy adult human volunteers

Next Previous
Trial Profile

A prospective, randomized, double blind, single dose, placebo-controlled study to evaluate pharmacokinetics, safety and tolerability of ZYBK2 in healthy adult human volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZYBK 2 (Primary) ; ZYBK 2 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Zydus Cadila; Zydus Lifesciences

Most Recent Events

  • 04 Nov 2020 Status changed from planning to recruiting.
  • 06 Mar 2020 New trial record
  • 03 Mar 2020 According to a Zydus Cadila media release, the company has received an approval from the Drug Controller General of India (DCGI) to initiate this phase I trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top